GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2- M enrichment in A549 cells

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1846-1850

  Miquel, Karine ^a   Pradines, Anne ^a   Sun, Jiazhi ^b   Qian, Yimin ^c   Hamilton, Andrew D ^c   Sebti, Saïd M ^b   Favre, Gilles ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPACTIN; DNA FRAGMENT; GERANYLGERANYLTRANSFERASE I INHBITOR; GGTI 298; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; DNA CONTENT; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ALKYL AND ARYL TRANSFERASES; APOPTOSIS; BENZAMIDES; CELL DIVISION; ENZYME INHIBITORS; G0 PHASE; G1 PHASE; G2 PHASE; HUMANS; LUNG NEOPLASMS; METHIONINE; MITOSIS; TRANSFERASES; TUMOR CELLS, CULTURED;

EID: 0031004491     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Casey, P. J. Biochemistry of protein prenylation. J. Lipid Res., 33: 1731-1740, 1992.
2. Sebti, S. M., and Hamilton, A. D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther., in press, 1997.
3. James, G. L., Goldstein, J, L., and Brown, M. S. Polylysine, and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem., 270: 6221-6226, 1995.
4. Lerner, E. C., Qian, Y. M., Hamilton, A. D., and Sebti, S. M. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol. Chem., 270: 26770-26773, 1995.
5. McGuire, T. F., Qian, Y. M., Vogt, A., Hamilton, A. D., and Sebti, S. M. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J. Biol. Chem., 271: 27402-27407, 1996.
6. 1 to S phase transition in mouse fibroblasts. Oncogene, 13: 1991-1999, 1996.
7. Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J., and Brown, M. S. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell, 62: 81-88, 1990.
8. Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibitors-ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
9. Buss, J. E., and Marsters, J. C. Farnesyl transferase inhibitors: the successes and surprises of a new class of potential cancer chemotherapeutics. Chem. Biol., 2: 787-791, 1995.
10. 1. Science (Washington DC), 269: 1270-1272, 1995.
11. Miquel, K., Pradines, A., and Favre, G. Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Biochem. Biophys. Res. Commun., 225: 869-876, 1996.
12. Lerner, E. C., Qian, Y. M., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J. Z., Cox, A. D., Der, C. J., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem., 270: 26802-26806, 1995.
13. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labelling of DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
14. Crick, D. C., Waechter, C. J., and Andres, D. A. Utilization of geranylgeraniol for protein isoprenylation in C6 glial cells. Biochem. Biophys. Res. Commun., 205: 955-961, 1994.
15. McGuire, T. M., and Sebti, S. M. Geranylgeraniol and lovastatin: a novel approach to blocking oncogene H-Ras processing and signaling while restoring protein geranylgeranylation and preventing cytotoxicity. Oncogene, 14: 305-312, 1997.